Acknowledgments

Clinical Infectious Diseases

Volumn 51, Issue 3, 2010, Pages 366-367

  Chang, Kwok Chiu ^a   Leung, Chi Chiu ^a  

^a DEPARTMENT OF HEALTH   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ALBUMIN BLOOD LEVEL; DRUG DOSE ESCALATION; HUMAN; LETTER; LIVER TOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; TREATMENT PLANNING; TUBERCULOSIS; NOTE; TOXIC HEPATITIS;

ANTITUBERCULAR AGENTS; DRUG-INDUCED LIVER INJURY; HUMANS; ISONIAZID; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS;

EID: 78049504801     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/654806     Document Type: Letter

References (8)

1. Sharma SK, Singla R, Sarda P, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010; 50:833-839.
2. Saukkonen J. Challenges in reintroducing tuberculosis medications after hepatotoxicity. Clin Infect Dis 2010; 50:840-842.
3. Tahaoǧlu K, Ataç G, Sevim T, et al. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2001; 5: 65-69.
4. Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculosis therapy: clinical profile and reintroduction of therapy. J Clin Gastroenterol 1996; 22:211-214.
5. Hong Kong Chest Service/Tuberculosis Research Centre MMRC. A double-blind placebocontrolled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145:36-41.
6. Chang KC, Leung CC, Yew WW, et al. Hepatotoxicity of pyrazinamide: cohort and casecontrol analyses. Am J Respir Crit Care Med 2008; 177:1391-1396.
7. Chang KC, Leung CC. The best approach of reintroducing tuberculosis treatment after hepatotoxicity is still open to debate [letter]. Clin Infect Dis 2010; 51(3):366-367 (in this issue).
8. Sharma SK, Singla R, Sarda P, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010; 50:833-839.